Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04018248
Other study ID # BR-101801-CT-101
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date April 21, 2020
Est. completion date March 2024

Study information

Verified date February 2024
Source Boryung Pharmaceutical Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I-II, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects with relapsed/refractory B cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), and peripheral T cell lymphoma (PTCL). The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory Peripheral T-cell lymphoma(PTCL) at a dose of BR101801 identified in Phase Ia. Once the RP2D has been determined in Phase Ia (dose escalation), Phase Ib (dose expansion) will commence.


Description:

1. Phase Ia (Dose Escalation) Primary Objectives - To assess the safety and tolerability of BR101801 in patients with relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL. - To assess DLT and to determine the MTD and/or the RDE dose for BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression. SecondaryObjectives - To characterize the plasma and urine PK of BR101801. - To assess the preliminary antitumor activity of BR101801. 2. Phase Ib (Dose Expansion) Primary Objectives • To assess the safety and tolerability of BR101801 at the RP2D dose in subjects with relapsed/refractory Peripheral T-cell lymphoma (PTCL). SecondaryObjectives - To assess clinical activity of BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression. - To assess the plasma PK of BR101801. OUTLINE: This is a Phase I, multi-center, open-label, FIH study. The safety monitoring committee(SMC) will be responsible for safety oversight.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date March 2024
Est. primary completion date September 21, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility <Inclusion Criteria> 1. Patients must sign an informed consent document 2. Female or male patients aged = 18 years. 3. ECOG performance status = 2. 4. Life expectancy more than 3 months. 5. Phase Ia:Patients with relapsed and/or refractory relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL diagnosed with World Health Organization (WHO) classification 6. Phase Ib: Subjects with PTCL NOS, PTCL AITL, Nodal PTCL with TFH and PTCL FTCL. 7. Patients have measurable disease based on the appropriate tumor type criteria( Phase Ib only) 8. Have a current need for systemic therapy, the assessment of the investigator. 9. An archival or fresh tumor tissue (ie, tissue block or series of at least 5 slides, up to 15 slides) is required and should be provided during the Screening Visit for Lymphoma subjects. Local review of pathology is required for study entry in Phase Ib only. 10. Phase Ia subjects should be prepared to undergo a fresh tumor biopsy during the study (tumor biopsies will be obtained from 1 to 2 subjects per cohort in Phase Ia). 11. Subject having laboratory values defined as: - Creatinine clearance (measured or calculated per institutional standard practice) = 60 mL/min. GFR can also be used in place of creatinine clearance. - Total bilirubin < 1.5 × ULN, except for subjects with Gilbert's syndrome who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin < 1.5 × ULN. - ALT < 2.5 × ULN, except for subjects who have tumor involvement of the liver, who are included if ALT < 5 × ULN. - AST < 2.5 × ULN, except for subjects that have tumor involvement of the liver, who are included if AST < 5 × ULN. - Absolute neutrophil count > 1.0 × 109/L. - Platelet count > 75 × 109/L. - Hemoglobin > 8 g/dL. <Exclusion Criteria> 1. Presence of overt leptomeningeal or active CNS metastases, or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks. Patients with treated brain metastases should be neurologically stable and off steroids for at least 2 weeks before administration of any study treatment. 2. Impaired cardiac function or clinically significant cardiac disease 3. Patients with interstitial pneumonia or history of drug-induced interstitial pneumonia/pneumonitis. 4. Human immunodeficiency virus (HIV) infection. 5. Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (HCVAb). 6. Chronic liver disease or chronic hepatitis 7. Any gastrointestinal disorders interfering with study drug absorption or are unable to swallow tablets or capsules. 8. Malignant disease, other than that being treated in this study. 9. Prior PI3K inhibitor will be accepted in the dose escalation part of the study (Phase Ia) only. 10. For patients with lymphoma: - Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon [INF], and toxin immunoconjugates) or any experimental therapy within 3 weeks or 5 half lives, whichever is shorter, before the first dose of study treatment. - Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment. - Unconjugated monoclonal antibody therapies < 6 weeks before the first dose of study treatment. 11. Patients receiving systemic chronic steroid therapy or any immunosuppressive therapy (= 10 mg/day prednisone or equivalent). 12. Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment. 13. Use of hematopoietic colony-stimulating growth factors, thrombopoietin mimetics, or erythroid-stimulating agents = 2 weeks prior to start of study drug. 14. Patients with a history of stroke or having active neurological symptoms, with the exception of chronic conditions which, in the opinion of the neurologist, Investigator, and the Sponsor, would not impact ongoing neurologic assessments while on study treatment. 15. Active infection requiring systemic or antiviral antibiotic therapy. 16. Subjects with active CMV infection. 17. Subjects receiving moderate or potent CYP3A4 inhibitors or inducers and are unable to withdraw until 2 weeks or 5 times longer than the half-life, whichever is shorter, before the first dose of study treatment. 18. Major surgery within 2 weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery). 19. Radiotherapy within 2 weeks of the first dose of study treatment, except for palliative radiotherapy to a limited-field, such as for the treatment of bone pain or a focally painful tumor mass. 20. Presence of CTCAE = Grade 2 toxicity (except alopecia, peripheral neuropathy, and ototoxicity, which are excluded if = CTCAE Grade 3) due to prior cancer therapy. 21. Participation in an interventional, investigational study within 2 weeks or 5 half-lives, whichever is shorter, of the first dose of study treatment. 22. Any medical condition that would, in the Investigator's judgment, prevent the subject's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results. 23. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test.

Study Design


Intervention

Drug:
BR101801 (Phase Ia)
Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
BR101801 (Phase Ib)
Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.

Locations

Country Name City State
Korea, Republic of Inje University Busan Paik Hospital Busan
Korea, Republic of National Cancer Center Goyang-si Gyeonggi-do
Korea, Republic of Chonnam National University Hwasun Hospital Hwasun Jeollanam-do
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul national university hospital Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
United States Henry Ford Hospital Detroit Michigan

Sponsors (1)

Lead Sponsor Collaborator
Boryung Pharmaceutical Co., Ltd

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determination of the MTD and RDE based on DLTs during Cycle 1 (Phase Ia ) The recommended dose is determined by the number of patients who experience a dose limiting toxicity (DLT). From baseline to Week 4
Primary Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability of BR101801 when administered at the MTD or recommended dose (Phase Ia and Ib) To evaluate safety and tolerability the aggregate review will include but is not limited to:
CTCAE TEAEs, treatment-related TEAEs, Grade 3 or higher TEAEs, Grade 3 or higher treatment-related TEAEs, serious treatment-related TEAEs, and TEAEs leading to death.
Laboratory results;
Vital signs;
ECGs;
Physical examination
ECOG performance status
through study completion, and about average of 1 year
Secondary Cmax Maximum concentration obtained directly from the observed concentration versus time data. Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15
Secondary AUC(0-inf) Area under the plasma concentration-time curve from time zero extrapolated to infinity, calculated by linear up/log down trapezoidal summation Cycle1( each cycle is 28 days) Day 1
Secondary AUC(0-last) Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, Pre-dose to 24 hours after dosing
Secondary AUC(0-tau) Area under the plasma concentration-time curve from time zero during a dosing interval Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, dosing interval: 24 or 12 hours
Secondary Ae Cumulative amount of unchanged drug excreted in urine Cycle 1( each cycle is 28 days)Day 15, Pre-dose to 12 hours for BID dosing and Pre-dose to 24 hours for QD dosing
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT02057185 - Occupational Status and Hematological Disease
Active, not recruiting NCT04240704 - Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Active, not recruiting NCT03280160 - Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab Phase 2
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT00038025 - A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT02231853 - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections Phase 1
Recruiting NCT05417165 - Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT04028531 - Understanding Chronic Lymphocytic Leukemia
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Completed NCT02910583 - Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) Phase 2
Completed NCT01527045 - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Phase 2
Recruiting NCT04679012 - Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation Phase 2
Recruiting NCT05405309 - RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia Phase 1/Phase 2
Active, not recruiting NCT05023980 - A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 3
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer